© Drug Hunter Inc. 2018-2023
Home > “compound 15a”
reversible ATX inhibitor w/ alt. binding mode
in vivo PD observed on oral dosing
from HTS screen and opt.
Bioorg. Med. Chem. Lett., Nov. 4, 2020
Novartis, Horsham, UK / Basel, CH
“compound 15a” (Novartis reversible in vivo ATX inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year